A Phase 2 interventional study of TG-0054 (2.24 mg/kg) and TG-0054 (3.14 mg/kg) in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease, sponsored by GPCR Therapeutics, Inc.. Completed at 6 sites in Taiwan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by GPCR Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Multiple Myeloma with a site in Taiwan — 19 open to participants now, 33 under way, 23 of them phase 3. Multiple Myeloma · Taiwan.
Among the 71 studies in Multiple Myeloma with a site in Taiwan, this one is the 60th largest by enrollment of the 64 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 in phase 2, and was the 3rd registered.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →19 of the 71 studies in Multiple Myeloma with a site in Taiwan are open now. Recruiting first, the newest first:
AbbVie · Sites in Taiwan, United States, Israel and 1 more country
Ages 18+
AstraZeneca · Sites in Taiwan, United States, Australia and 15 more countries
Ages 18–130
AstraZeneca · Sites in Taiwan, United States, Australia and 12 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Taiwan, United States, Australia and 15 more countries
Ages 18+
Kaohsiung Medical University Chung-Ho Memorial Hospital · Sites in Taiwan
Ages 18–80
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 41 · Phase 4 3
First in 2005; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.
Median enrollment 431 across the 64 interventional studies, 400 across the 7 observational. Of the 33 that completed or were terminated, 20 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 71 have an industry lead sponsor. The 10 most frequent:
GPCR Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
GPCR Therapeutics, Inc. has 4 studies filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
10 of the studies in Multiple Myeloma with a site in Taiwan that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05317416Phase 3PfizerStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | 2027-08-04 |
Add all 10 to your calendar (.ics) → With an account.
Among the 71 studies in Multiple Myeloma with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For females, one of the following criteria must be fulfilled:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Drug: TG-0054 (2.24 mg/kg)
TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Drug: TG-0054 (3.14 mg/kg)
Drug page: BurixaforStudies of BurixaforBurixafor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Drug page: BurixaforStudies of BurixaforBurixafor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Number of Patients Who Achieved Mobilization Success of Hematopoietic Stem Cells in Patients With Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD).
Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.
Time frame: 1 week
Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
Fold Increase of Circulating CD34+ Cell Counts in Peripheral Blood.
Time frame: Baseline, 3 hours and 6 hours after infusion
Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD.
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
Time frame: 36 hrs after infusion
Circulating CD34+ Cell Counts in Peripheral Blood.
Time frame: Baseline, 3 hours and 6 hours after infusion
| Milestone | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Started | 7 | 13 |
| Received at least one dose | 7 | 12 |
| Completed | 4 | 3 |
| Not completed | 3 | 10 |
| Withdrew: Peak cd34+ cell count in pb < 10 cell/ul | 3 | 9 |
| Withdrew: Not received at least one dose | 0 | 1 |
Patients who met the target CD34+ cell collection of ≧2 x 106 cells/kg after two apheresis sessions were classified as achieving mobilization success.
| participants | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| MM | 1 | 1 |
| NHL | 1 | 0 |
| HD | 0 | 0 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| ng/mL | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 20971 ± 6995 | 29665 ± 18583 |
| fold | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD) | All Patients |
|---|---|---|---|
| Fold increase (3 hours after infusion) | 7.0 ± 5.9 | 6.1 ± 6.1 | 6.4 ± 5.9 |
| Fold increase (6 hours after infusion) | 7.8 ± 7.2 | 7.8 ± 10.4 | 7.8 ± 9.1 |
| Fold increase (Maximum increase) | 9.3 ± 7.5 | 10.3 ± 8.9 | 10.0 ± 8.4 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| hr | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Time at Which Maximum Plasma Concentration is Observed (Tmax) of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 0.25 ± 0 | 0.25 ± 0 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| hr | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Terminal Elimination Half-life (t1/2) of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 4.65 ± 0.4 | 4.28 ± 0.6 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| 1/hr | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Terminal Elimination Rate Constant (λz) of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 0.15 ± 0.01 | 0.16 ± 0.02 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| hr*ng/mL | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Time t of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 43610 ± 7034 | 55814 ± 12153 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| hr*ng/mL | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| The Area Under the Plasma Concentration Time Curve (AUC) From 0 Hours to Infinity of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 43713 ± 7039 | 55920 ± 12170 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| mL/ hr/kg | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Clearance (CL) of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 52.5 ± 9.4 | 58.6 ± 13.0 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| mL/kg | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Volume of Distribution at the Terminal State (Vz) of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 351 ± 62 | 366 ± 112 |
Plasma concentrations of TG-0054 were determinate by validated LC-MS/MS method.
| mL/kg | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| Volume of Distribution at Steady State (Vss) of TG-0054 in 12 Consented Patients With MM, NHL or HD. | 179 ± 64 | 193 ± 76 |
| cells/μL | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL) + Hodgkin Disease (HD) | All Patients |
|---|---|---|---|
| PB CD34+ count (Baseline) | 1.0 ± 0.7 | 0.9 ± 0.5 | 1.0 ± 0.6 |
| PB CD34+ count (3 hours after infusion) | 5.7 ± 4.0 | 4.0 ± 2.1 | 4.6 ± 2.9 |
| PB CD34+ count (6 hours after infusion) | 6.3 ± 3.9 | 4.3 ± 2.7 | 5.1 ± 3.3 |
| PB CD34+ count (Maximum increase) | 7.8 ± 4.4 | 5.2 ± 3.7 | 6.5 ± 4.1 |
Collected over The whole study period, from Visit 1 (screening, day -14) to Visit 9 (7 days after the last dose). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TG-0054 (2.24 mg/kg) | — | 2/7 (28.6%) | 6/7 (85.7%) |
| TG-0054 (3.14 mg/kg) | — | 6/12 (50%) | 8/12 (66.7%) |
| Event | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| ADMISSION FOR PREPARATION OF PERIPHERAL BLOOD STEM CELL HARVESTSurgical and medical procedures | 0/7 | 3/12 |
| HOSPITALIZATION FOR BONE MARROW TRANSPLANTATIONSurgical and medical procedures | 1/7 | 0/12 |
| AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATIONSurgical and medical procedures | 1/7 | 0/12 |
| AUTOLOGOUS STEM CELL TRANSPLANTSurgical and medical procedures | 0/7 | 1/12 |
| TREATMENT OF NON-HODGKIN LYMPHOMASurgical and medical procedures | 0/7 | 1/12 |
| PEIPHERAL BLOOD STEM CELL HARVESTSurgical and medical procedures | 0/7 | 1/12 |
| Event | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) |
|---|---|---|
| DIZZINESSNervous system disorders | 2/7 | 1/12 |
| LEUKOCYTOSISBlood and lymphatic system disorders | 2/7 | 2/12 |
| ABDOMINAL PAINGastrointestinal disorders | 1/7 | 0/12 |
| ABNORMAL DATA OF INCREASE BILIRUBINInvestigations | 1/7 | 0/12 |
| CHEST TIGHTNESSRespiratory, thoracic and mediastinal disorders | 1/7 | 0/12 |
| CLONIC OF RIGHT KNEENervous system disorders | 1/7 | 0/12 |
| DIARRHEAGastrointestinal disorders | 1/7 | 1/12 |
| HYPERCALCEMIAMetabolism and nutrition disorders | 1/7 | 0/12 |
| HYPOCALCIUMMetabolism and nutrition disorders | 1/7 | 0/12 |
| HYPOKALEMIAMetabolism and nutrition disorders | 1/7 | 1/12 |
19 subjects met all eligibility criteria and received at least one dose of TG-0054.
| Age, Continuous(years) | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) | Total |
|---|---|---|---|
| Mean | 47.3 ± 15.5 | 52.4 ± 9.3 | 50.5 ± 11.8 |
| Sex: Female, Male(Participants) | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) | Total |
|---|---|---|---|
| Female | 4 | 7 | 11 |
| Male | 3 | 5 | 8 |
| Height(centimeters) | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) | Total |
|---|---|---|---|
| Mean | 162.7 ± 10.1 | 158.7 ± 8.6 | 160.2 ± 9.1 |
| Weight(kilogram) | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) | Total |
|---|---|---|---|
| Mean | 67.3 ± 23.1 | 60.6 ± 10.2 | 63.1 ± 15.9 |
| Body Mass Index(kilogram/ meter^2) | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) | Total |
|---|---|---|---|
| Mean | 25.1 ± 6.0 | 24.0 ± 3.0 | 24.4 ± 4.2 |
| Diagnosis(participants) | TG-0054 (2.24 mg/kg) | TG-0054 (3.14 mg/kg) | Total |
|---|---|---|---|
| Multiple myeloma | 3 | 4 | 7 |
| Non-Hodgkin lymphoma | 3 | 7 | 10 |
| Hodgkin disease | 1 | 1 | 2 |
The record gives a start of Feb 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Burixafor
GPCR Therapeutics, Inc.